Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts

Radiotherapy and Oncology

Volumn 78, Issue 2, 2006, Pages 138-145

  Huxham, Lynsey A ^a   Kyle, Alastair H ^a   Baker, Jennifer H E ^a   McNicol, Krista L ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Hypoxia; Tirapazamine; Tumour; Vasculature

Indexed keywords

TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD VESSEL; CANCER SURGERY; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MOUSE; NECROSIS; NONHUMAN; PERFUSION; PRIORITY JOURNAL; STAINING; TIME; TUMOR XENOGRAFT; VASCULAR DISEASE; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; BROMODEOXYURIDINE; CELL HYPOXIA; CELL PROLIFERATION; COLORING AGENTS; FEMALE; HCT116 CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; MICE, SCID; NECROSIS; REGIONAL BLOOD FLOW; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 33644764902     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.01.002     Document Type: Article

References (48)

1. D.J. Chaplin, R.E. Durand, and P.L. Olive Acute hypoxia in tumour: implications for modifiers of radiation effects Int J Radiat Oncol Biol Phys 12 1986 1279 1282
2. D.J. Chaplin, P.L. Olive, and R.E. Durand Intermittent blood flow in a murine tumour: radiobiological effects Cancer Res 47 1987 597 601
3. A.I. Minchinton, R.E. Durand, and D.J. Chaplin Intermittent blood flow in the KHT sarcoma-flow cytometry studies using Hoechst 33342 Br J Cancer 62 1990 195 200
4. D.W. Siemann, I.M. Johansen, and M.R. Horsman Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph Int J Radiat Oncol Biol Phys 40 1998 1171 1176
5. L.H. Gray, A.D. Conger, M. Ebert, S. Hornsey, and O.C. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 1953 638 648
6. L.A. Huxham, A.H. Kyle, J.H. Baker, L.K. Nykilchuk, and A.I. Minchinton Microregional effects of gemcitabine in HCT-116 xenografts Cancer Res 64 2004 6537 6541
7. R.K. Jain Delivery of molecular and cellular medicine to solid tumors Microcirculation 4 1997 3 21
8. R.K. Jain The next frontier of molecular medicine: delivery of therapeutics Nat Med 4 1998 655 657
9. A.H. Kyle, L.A. Huxham, A.S. Chiam, D.H. Sim, and A.I. Minchinton Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture Cancer Res 64 2004 6304 6309
10. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin Cancer Res 8 2002 878 884
11. A.W. Fyles, M. Milosevic, and R. Wong Oxygen predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 1998 149 156
12. M. Höckel, B. Vorndran, K. Schlenger, E. Baussmann, and P.G. Knapstein Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix Gynecol Oncol 51 1993 141 149
13. M. Höckel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
14. M. Nordsmark, M. Overgaard, and J. Overgaard Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 1996 31 39
15. M. Nordsmark, S.M. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother Oncol 77 2005 18 24
16. J.H. Kaanders, K.I. Wijffels, and H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
17. P.L. Olive, J.P. Banath, and C. Aquino-Parsons Measuring hypoxia in solid tumours - is there a gold standard? Acta Oncol 40 2001 917 923
18. A. Yaromina, T. Holscher, and W. Eicheler Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 76 2005 206 212
19. P.J. Hoskin, A. Sibtain, F.M. Daley, M.I. Saunders, and G.D. Wilson The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma Radiother Oncol 72 2004 159 168
20. H.L. Janssen, F.J. Hoebers, and D. Sprong Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors Radiother Oncol 70 2004 91 97
21. J. Bussink, J.H. Kaanders, and A.J. van der Kogel Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers Radiother Oncol 67 2003 3 15
22. M. Nordsmark, J. Loncaster, and C. Aquino-Parsons Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas Radiother Oncol 67 2003 35 44
23. R.E. Airley, J. Loncaster, and J.A. Raleigh GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding Int J Cancer 104 2003 85 91
24. P.L. Olive, C. Aquino-Parsons, and S.H. MacPhail Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer Cancer Res 61 2001 8924 8929
25. R.H. Thomlinson, and L.H. Gray The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 1955 539 549
26. G.E. Adams, E.D. Clarke, and I.R. Flockhart Structure-activity relationships in the development of hypoxic cell radiosensitizers Int J Radiat Biol 35 1978 133 150
27. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509 518
28. J.M. Brown, and M.J. Lemmon SR 4233 - a tumor specific radiosensitizer active in fractionated radiation regimes Radiother Oncol 20 1991 151 156
29. K. Laderoute, P. Wardman, and A.M. Rauth Molecular mechanisms for the hypoxia dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) Biochem Pharmacol 37 1988 1487 1495
30. K.A. Biedermann, J. Wang, R.P. Graham, and J.M. Brown SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures Br J Cancer 63 1991 358 362
31. E.M. Zeman, J.M. Brown, M.J. Lemmon, V.K. Hirst, and W.W. Lee SR-4233: a bioreductive agent with high selective toxicity for hypoxic cells Int J Radiat Biol Phys 12 1986 1239 1242
32. E.M. Zeman, V.K. Hirst, M.J. Lemmon, and J.M. Brown Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR-4233 Radiother Oncol 12 1988 209 218
33. M.J. Dorie, and J.M. Brown Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine Cancer Chemother Pharmacol 39 1997 361 366
34. M.J. Dorie, D. Menke, and J.M. Brown Comparison of the enhancement of tumor response to fractionated irradiation by SR 4233 (Tirapazamine) and by nicotinamide Int J Radiat Oncol Biol Phys 28 1993 145 150
35. D.W. Siemann, and C.A. Hinchman Potentiation of cisplatin activity by the bioreductive agent tirapazamine Radiother Oncol 47 1998 215 220
36. M.J. Dorie, and J.M. Brown Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin Cancer Res 53 1993 4633 4636
37. M.S. Kovacs, D.J. Hocking, J.W. Evans, B.G. Siim, B.G. Wouters, and J.M. Brown Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin Br J Cancer 80 1999 1245 1251
38. R.E. Durand, and P.L. Olive Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice Radiat Oncol Invest 5 1997 213 219
39. K.O. Hicks, Y. Fleming, B.G. Siim, C.J. Koch, and W.R. Wilson Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model Int J Radiat Oncol Biol Phys 42 1998 641 649
40. A. Kyle, and A.I. Minchinton Measurement of delivery and metabolism of tirapazamine through tumour tissue using the multilayered cell culture model Cancer Chemother Pharmacol 43 1999 213 220
41. T. Fuchs, G. Chowdhury, C.L. Barnes, and K.S. Gates 3-Amino-1,2,4- benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (Tirapazamine) J Org Chem 66 2001 107 114
42. A.H. Kyle, L.A. Huxham, J.H. Baker, H.E. Burston, and A.I. Minchinton Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent Cancer Res 63 2003 5707 5711
43. K.O. Hicks, F.B. Pruijn, J.R. Sturman, W.A. Denny, and W.R. Wilson Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures Cancer Res 63 2003 5970 5977
44. 2 gradients in window chamber tumours: impact on tumour hypoxia Br J Cancer 79 1999 1717 1722
45. J.E. Moulder, and S. Rockwell Tumor hypoxia: its impact on cancer therapy Cancer Metastases Rev 5 1987 313 341
46. V.K. Langmuir, J.A. Rooker, M. Osen, H.L. Mendonca, and K.R. Laderoute Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts Cancer Res 54 1994 2845 2847
47. G.G. Dark, S.A. Hill, V.E. Prise, G.M. Tozer, G.R. Pettit, and D.J. Chaplin Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1997 1829 1834
48. G.M. Tozer, C. Kanthou, C.S. Parkins, and S.A. Hill The biology of the combretastatins as tumour vascular targeting agents Int J Exp Pathol 83 2002 21 38